# 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

> **NCT02579252** · PHASE2 · COMPLETED · sponsor: **Axon Neuroscience SE** · enrollment: 208 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** AADvac1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02579252
- **Lead sponsor:** Axon Neuroscience SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579252, "24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02579252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*